Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > REGULATORY
REGULATORY
- Deliberations on Specific Cases of Cost-Effective Assessments to Be Closed to the Public: Chuikyo
December 25, 2014
- Investigation Finds No Intentional Data Falsification from J-ADNI Study
December 25, 2014
- MHLW Orders Revision of Package Insert for Jevtana
December 24, 2014
- Novartis Pharma Should Take Thorough Measures to Prevent Worker Involvement in IITs: Health Minister
December 22, 2014
- New “Compassionate Use” System to Be Introduced in FY2015; Will Apply to Industry-Sponsored Trials as well as IITs
December 22, 2014
- Orphan Designation to Be Expanded to Include Intractable Diseases Affecting More than 50,000 Patients
December 22, 2014
- MHLW OKs New Indication for Nesp, Pediatric Dosages for Cancidas
December 19, 2014
- LDP to Begin Intensive Tax Debate from December 25
December 19, 2014
- MHLW Releases Discussion Outline of ICH Lisbon Meeting
December 18, 2014
- LDP Tax Panel Execs Eye Slight Cut of R&D Tax Deduction Cap
December 17, 2014
- Drug Makers Present Cases in Which PI Trials in Japanese Could Be Omitted in Multinational Studies: PMDA Workshop
December 17, 2014
- Japan Tax Reform Plan Will Be Compiled by Year-End: Abe
December 16, 2014
- Editor’s Pick: Five Healthcare News Headlines for Dec. 1 - 14
December 15, 2014
- JPMA Will Work to Secure Quality, Transparency of Clinical Research for Purpose of Advertising: Vice President
December 15, 2014
- LDP Healthcare Big Names Cruise to Victory in Lower House Poll
December 15, 2014
- Panel Reveals Final Report Calling for Legal Regulations for Clinical Research
December 12, 2014
- Outline of New Global Clinical Trial Guidelines Agreed On at ICH Confab in Lisbon
December 12, 2014
- Elplat, Elaspol Generics to Join NHI Price List on Dec. 12
December 11, 2014
- Wholesalers’ Negative Primary Margin on Sales Widens Slightly in First Half of FY2014: Ryukaikon
December 11, 2014
- Ryukaikon Members Hail High Price Settlements, but Fret over Fallout from Penalty Fee Cuts
December 11, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…